Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shouzu Ning Decoction No.2 (SND2) is a Traditional Chinese Medicine (TCM) herbal formulation developed by The First Affiliated Hospital of Zhejiang Chinese Medical University for the treatment of hand-foot skin reaction (HFSR). HFSR is a common dermatological toxicity associated with multikinase inhibitors (MKIs) such as sorafenib and sunitinib. SND2 is specifically tailored for patients exhibiting the TCM pattern of 'dampness-heat stasis syndrome.' The decoction is typically applied topically to reduce inflammation, alleviate pain, and promote skin healing in patients with grade 2 HFSR. Although a multi-center, randomized, double-blind, placebo-controlled trial was initiated to evaluate its efficacy and safety, the study was subsequently canceled by the investigator.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shouzu Ning Decoction No.2.